A Phase 2 interventional study of Alveltamig and Atezolizumab in Extensive Stage-Small Cell Lung Cancer (ES-SCLC), sponsored by AbbVie. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites. Extensive stage-small cell lung cancer (ES-SCLC) includes cases where disease has spread beyond one side of the chest. This study will evaluate the safety and efficacy of ABBV-706 in combination with atezolizumab and alveltamig in previously untreated ES-SCLC.
ABBV-706 and alveltamig are investigational drugs being developed for the treatment of ES-SCLC. This is an open-label study, meaning participants and doctors know which treatment is being given. Participants are placed into 1 of 2 treatment arms. Each arm receives a different dose of ABBV-706 in combination with alveltamig and atezolizumab. Adult participants with a diagnosis of previously untreated extensive stage-small cell lung cancer will be enrolled. Around 80 participants will be enrolled in the study at approximately 25 sites worldwide.
Participants will receive intravenous (IV) infusion of ABBV-706 in combination with IV infusion of atezolizumab and IV infusion of alveltamig. The estimated duration of the study is approximately 61 months.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, imaging scans, checking for side effects and completing questionnaires.
9,616 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.
This study's planned enrollment of 80 is above the median of 50 across 7,429 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AbbVie is the lead sponsor of 969 studies on the registry; 134 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 214 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive ABBV-706 dose A in combination with alveltamig and atezolizumab during the safety lead-in and dose expansion periods.
Drug: Alveltamig · Drug: Atezolizumab · Drug: ABBV-706
Participants will receive ABBV-706 dose B in combination with alveltamig and atezolizumab during the safety lead-in and dose expansion periods.
Drug: Alveltamig · Drug: Atezolizumab · Drug: ABBV-706
Intravenous
Intravenous
Intravenous
Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Objective response (OR) is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) as assessed by Blinded Independent Central Review (BICR) per RECIST v1.1 prior to subsequent anti-cancer therapy.
Time frame: Up to approximately 4 years
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 4 years
Progression-Free Survival (PFS) as Assessed by BICR Per RECIST v1.1
PFS is defined as the time from the date of randomization to the first documentation of radiographic disease progression per RECIST v1.1 based on BICR assessment or death from any cause, whichever occurs first.
Time frame: Up to approximately 3.5years
Disease Control Rate (DCR) as Assessed by BICR
DCR is defined as achieving an objective response (OR) or stable disease (SD) at any time prior to subsequent anti-cancer therapy, as assessed by BICR
Time frame: Up to approximately 4 years
Duration of Response (DoR) as Assessed by BICR
DoR is defined as time from the initial response of complete response (CR) or partial response (PR) until the first documentation of radiographic progressive disease (PD) or death from any cause, whichever occurs first, as assessed by BICR
Time frame: Up to approximately 4 years
Overall Survival
OS is defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 3.5 years
Percentage of Participants Achieving Molecular Response (≥50% Reduction)
Molecular response is defined as a ≥50% reduction in tumor fraction (TF) as measured by methylation-based circulating tumor DNA (ctDNA) assay (Guardant Reveal on the Infinity platform).
Time frame: Up to approximately 6 weeks
Percentage of Participants Achieving Complete Molecular Clearance (100% Reduction)
Complete molecular clearance is defined as 100% reduction in tumor fraction (TF), meaning TF becomes unquantifiable (below the limit of quantification \[LOQ\] of \<0.01% TF) from baseline (Cycle 1 Day 1) to Cycle 3 Day 1 as measured by methylation-based circulating tumor DNA (ctDNA) assay (Guardant Reveal on the Infinity platform).
Time frame: Up to approximately 6weeks
No study locations are listed for this record.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2031, 61 months later.
Of 162 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 72. This study's planned 61 months is above that.
Counting every sponsor, half of 554 studies reached it within 52 months; a quarter within 33 and three quarters within 88.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atezolizumab